Ozempic India launch: Novo Nordisk rolled out its blockbuster diabetes drug Ozempic in India, with monthly treatment starting at Rs 8,800 for four weeks, the company said. The popular once-a-week injection is priced at Rs 2,200 per week for the lowest dose at 0.25 mg in the country.
Ozempic (semaglutide) is a once-weekly injectable medicine approved in India for adults with uncontrolled type 2 diabetes, to be used alongside diet and exercise.
Also Read | A guide to GLP-1 side effects: What to expect and how to manage them
The product will be sold in a single-use pre-filled pen and comes in three strengths: 0.25 mg, 0.5 mg, and 1 mg. Each pen contains four weekly doses. Pricing shared by the company puts the 0.25 mg starter dose at Rs 8,800, followed by Rs 10,170 for 0.5 mg and Rs 11,175 for 1 mg.
Vikrant Shrotriya, Managing Director of Novo Nordisk India, said the launch is a key milestone for the company and positions Ozempic as an additional treatment option for Indian doctors. He added that the aim is to offer a therapy that supports better blood sugar control, weight management, and longer-term heart and kidney protection, delivered through an easy-to-use weekly pen.
Ozempic was first approved by the US FDA in 2017 for type 2 diabetes and has since seen widespread off-label use for weight loss due to its appetite-suppressing effects.
Novo Nordisk said the drug belongs to the GLP-1 receptor agonist class and helps lower blood sugar and HbA1c, influences appetite and food intake by acting on hunger-related brain pathways, supports weight loss in people with type 2 diabetes, and may reduce the risk of cardiovascular and kidney complications linked to diabetes.
